← Eichor
Study identifier: NCT06555393 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study

Condition: High Blood Sugar · High Blood Pressure · Overweight and Obesity  ·  Sponsor: University of Alberta

PhasePhase 1
Planned participants28
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersYes

About this study

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

This description comes directly from the study's public registry record.

Talk to the study team

Paulina Blanco Cervantes, MSc  ·  7804929506  ·  blancoce@ualberta.ca

Always discuss trial participation with your own doctor first.

Locations (1)

University of AlbertaEdmonton, Alberta, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06555393